Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 17/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005512 | 0.89 | HSP90AB1 (0.51) | OPRM1OPRK1OPRD1HSP90AB1HSP90AA1 | |
| SCHEMBL5005722 | 0.87 | OPRM1 (0.51) | OPRM1OPRK1OPRD1HSP90AB1HSP90AA1 | |
| SCHEMBL5010057 | 0.85 | OPRM1 (0.52) | OPRM1OPRK1OPRD1HSP90AB1HSP90AA1 | |
| SCHEMBL3627622 | 0.82 | OPRM1 (0.53) | OPRM1OPRK1OPRD1HSP90AB1 | |
| SCHEMBL4558724 | 0.78 | OPRM1 (0.73) | OPRM1OPRK1OPRD1HSP90AB1HSP90AA1 | |
| SCHEMBL5004994 | 0.76 | HSP90AB1 (0.48) | OPRM1HSP90AB1HSP90AA1 | |
| SCHEMBL17584087 | 0.76 | HSP90AA1 (0.35) | OPRM1HSP90AB1HSP90AA1 | |
| SCHEMBL15613351 | 0.74 | HSP90AB1 (0.67) | OPRM1OPRK1OPRD1HSP90AB1HSP90AA1 | |
| SCHEMBL4368064 | 0.74 | HSP90AB1 (0.69) | OPRM1OPRK1OPRD1HSP90AB1HSP90AA1 | |
| SCHEMBL5005802 | 0.74 | HSP90AB1 (0.54) | OPRM1OPRK1OPRD1HSP90AB1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | claimed |
| WO-2008130879-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | HSF1, HSP90AB1, TPH1 | OPRM1 2733/4885OPRK1 478/4885OPRD1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.